Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Glaucoma: Overview01:25

Glaucoma: Overview

672
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
672
Chemical Synapses01:26

Chemical Synapses

8.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

516
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vogt-Koyanagi-Harada Disease Mimicking Idiopathic Intracranial Hypertension.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Obstructive Sleep Apnea in Idiopathic Intracranial Hypertension: Systematic Review and Meta-Analysis.

Neuro-ophthalmology (Aeolus Press)·2025
Same author

Mitochondrial Chronic Progressive External Ophthalmoplegia.

Brain sciences·2024
Same author

Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies.

Neuro-ophthalmology (Aeolus Press)·2022
Same author

Course and Predictors of Visual Outcome of Idiopathic Intracranial Hypertension.

Neuro-ophthalmology (Aeolus Press)·2022
Same author

Risk factors and visual outcome of Non-Arteritic Ischemic Optic Neuropathy (NAION): Experience of a tertiary center in Kuwait.

PloS one·2021

Related Experiment Video

Updated: Aug 10, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.3K

Ocular Myasthenia Gravis: A Current Overview.

Raed Behbehani1

  • 1Neuroophthalmology Unit, Ibn Sina Hospital, Kuwait City, Kuwait.

Eye and Brain
|February 13, 2023
PubMed
Summary
This summary is machine-generated.

Ocular myasthenia gravis (OMG) diagnosis involves clinical assessment and antibody assays for acetylcholine receptors (AchR) and others. Treatment includes cholinesterase inhibitors, steroids, and immunosuppressants, with a need for better biomarkers.

Keywords:
anti-MuSK antibodiesanti-acetyl-choline receptor antibodygeneralized myastheniaocular myasthenia

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Related Experiment Videos

Last Updated: Aug 10, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Area of Science:

  • Neurology
  • Immunology
  • Ophthalmology

Background:

  • Ocular myasthenia gravis (OMG) is a neuromuscular junction disorder caused by autoantibodies against post-synaptic proteins.
  • Diverse autoimmune mechanisms underlie myasthenia, influenced by autoantibody type.

Purpose of the Study:

  • To review current diagnostic and therapeutic strategies for Ocular Myasthenia Gravis (OMG).
  • To highlight recent advancements in OMG management.

Main Methods:

  • Review of clinical assessment methods, including ice and electrophysiologic tests (single-fiber electromyography).
  • Analysis of serological antibody assays for acetylcholine receptors (AchR), muscle-specific tyrosine kinase (MusK), and low-density lipoprotein 4 (LPR4).
  • Evaluation of current and emerging immunosuppressive therapies (e.g., azathioprine, Rituximab, eculizumab).

Main Results:

  • Diagnosis relies on clinical evaluation and specific autoantibody tests (AchR, MusK, LPR4).
  • Emerging autoantibodies like anti-cortactin and anti-agrin require further research for diagnostic and pathogenic roles.
  • Treatment involves pyridostigmine, steroids, and various immunosuppressants, but evidence on altering disease course is limited.

Conclusions:

  • There is a need for reliable biomarkers to assess OMG severity and treatment response.
  • Clinicians should monitor for myasthenic syndromes in patients using immune checkpoint inhibitors.
  • Further research is needed to clarify the role of novel autoantibodies and optimize OMG treatment strategies.